Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Morphan" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Morphan is a chemical compound. It is the base of the benzomorphan family of drugs.
Opioid receptor antagonist compounds
Owner:ALCASYNN PHARMA +1
Benzomorphan compounds
ActiveUS8426594B2Reducing desired analgesic effectReduce and prevent constipationBiocideNervous disorderOpioid AgonistBenzomorphan
The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R1, R2, R3, R4, and R5 are as defined herein. These compounds are useful for treating constipation preferably constipation caused by mu-opioid agonist therapy.
Owner:PURDUE PHARMA LP
Benzomorphan Analogs and the Use Thereof
ActiveUS20140135351A1Reduce and prevent constipationReduction and prevention of constipationBiocideNervous disorderBenzomorphanConstipation
The present invention is directed to Benzomorphan Analog compounds of the Formula I″, Formula IA″, Formula IB″, Formula IC″, or Formula ID″ as shown below; and related Formula I′, Formula IA′, Formula IB′, Formula IC′, or Formula ID′; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R1, R2a, R2b, R3 and R4 are as defined herein.Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
Owner:PURDUE PHARMA LP
6-aminomorphinane derivatives, method for production and use thereof
InactiveUS7538118B2High therapeutic application potentialLong analgesically effective periodBiocideNervous disorderCombinatorial chemistryBiochemical engineering
Owner:CHIRONWELLS
Compositions and Methods For Making Alkaloid Morphinans
Methods that may be used for the manufacture of a class of chemical compounds known as morphinans, including neopine, are provided. Compositions useful for the synthesis of morphinans, including neopine, are also provided.
Owner:WILLOW BIOSCI INC
Benzomorphan analogs and the use thereof
ActiveUS9056836B2Eliminate side effectsEliminate the effects ofNervous disorderOrganic chemistryBenzomorphanTreatment pain
The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R1, R2a, R2b, R3 and R4 are as defined herein.Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
Owner:PURDUE PHARMA LP
Stable medicinal compositions containing 4,5-epoxymorphinane derivatives
A stable pharmaceutical composition includes a 4,5-epoxy-morphinan derivative, and includes at least one of the group consisting of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar, and a surfactant.
Owner:TORAY IND INC
Process for the preparation of morphinane analogues
ActiveUS8546572B2High yieldImprove production yieldOrganic chemistryCombinatorial chemistrySubstituent
Owner:SUN PHARMA INDS
BENZOMORPHAN ANALOGS And Use Thereof
ActiveUS20170073313A1Simple processEffective analgesiaNervous disorderOrganic chemistryBenzomorphanPharmaceutical medicine
The invention provides compounds as represented by Formula I or I′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R1, R2, R2a, R3, and R4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and / or ORL-1 receptors.
Owner:PURDUE PHARMA LP
Tandem Process for Preparing N-Alkyl Morphinans
The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis / alkylation reactions for the synthesis of N-alkyl morphinans.
Owner:SPECGX LLC
Preparation of 6-Keto, 3-Alkoxy Morphinans
The present invention provides processes for the preparation of saturated 6-keto, 3-alkoxy morphinans from unsaturated 6-hydroxy, 3-hydroxy morphinans, In particular, the invention provides processes that utilize catalytic isomerization and alkylation reactions for the preparation of saturated 6-keto, 3-alkoxy morphinans.
Owner:MALLINCKRODT INC
Nitrogen Containing Morphinan Derivatives and the Use Thereof
The application is directed to compounds of Formula I-Aand pharmaceutically acceptable salts and solvates thereof, wherein R1a-R3a, R4, Y, and Z are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
Owner:PURDUE PHARMA LP
Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
It is intended to provide a morphinan derivative represented by the following general formula (I): (I) wherein R<1> represents methyl, cyclopropylmethyl, etc.; R<2> and R<3> represent each hydroxy, methoxy, acetoxy, etc.; Y and Z represent each a valence bond, -(C=O)-, etc.; X represents a C2-5 carbon chain constituting a part of the cyclic structure (wherein one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen); (R<4>)k represents an optionally substituted fused benzene ring, carbonyl, etc.; R<9> represents hydrogen, etc.; R<10> and R<11> may be bonded together to form -O-; and R<6> represents hydrogen, etc.The above-described compound is useful as a novel remedy or preventive for urinary frequency or urinary incontinence showing an isolated side effect. Moreover, it is useful in a method for treating or preventing the above diseases and utilization for these diseases.
Owner:TORAY IND INC
Benzomorphan Compounds
ActiveUS20100324080A1Reduce and prevent constipationReduction and prevention of constipationBiocideNervous disorderOpioid AgonistMedicine
The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R1, R2, R3, R4, and R5 are as defined herein. These compounds are useful for treating constipation preferably constipation caused by mu-opioid agonist therapy.
Owner:PURDUE PHARMA LP
Preparation of Saturated Ketone Morphinan Compounds by Catalytic Isomerization
The present invention provides processes for the preparation of saturated ketone morphinan compounds by catalytic isomerization. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an allyl-transition metal catalyst.
Owner:SPECGX LLC
Quinolinomorphinane derivatives and medicinal use thereof
InactiveUS6172078B1Good effectCuring and preventing worseningBiocideOrganic chemistryCerebral paralysisQuinoline
The present invention provides a quinolinomorphinan derivative or a pharmacologically acceptable acid addition salt thereof, and an agent for curing or preventing cerebral disorders composed of the derivative and salt thereof, which is represented by the following formula (I):(wherein R1 represents cyclopropylmethyl or the like; R2 and R3 independently represent hydroxy, methoxy, or the like; R4 represents hydrogen, methyl, amino or the like; and (R5)m represents hydrogen, substituted benzo, or the like. The compounds of the present invention prevent damages of the cerebral nerve cells and are useful as medicine for curing or preventing various cerebral diseases such as cerebral stroke, traumatic cerebral diseases, cerebral edema, and cerebral neurodegenerative diseases. The compounds of the present invention also ameliorate the after-effects of these diseases and prevent the recurrence of these diseases by inhibiting various ischemic, hemorrhagic or traumatic cerebral disorders, and damages of the cerebral nerve cells caused by various nerve degenerations.
Owner:TORAY IND INC
6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN
InactiveUS20130289060A1Lessened liability constipationLessened respiratory depressionBiocideNervous disorderAnthraceneAmino derivatives
Therapeutic or prophylactic agent for biliary diseases
ActiveCN102711759AGood treatment effectSignificant preventive effectOrganic active ingredientsOrganic chemistryDiseaseBiliary tract
Disclosed is a novel medicinal agent which has an excellent therapeutic effect on biliary diseases and is therefore is useful for the treatment or prevention of biliary diseases. Specifically disclosed is a therapeutic or prophylactic agent for biliary diseases, which comprises a compound having a specific morphinan backbone typified by compound 1 or a pharmacologically acceptable acid addition salt thereof as an active ingredient.
Owner:TORAY IND INC
Dicranostigma leptopodum (maxim) fedde alkaloid effective part preparation method
ActiveCN105250391AImprove solubilityEasy to separateAntipyreticAnalgesicsIsoquinolineChemical compound
The present invention discloses a dicranostigma leptopodum (maxim) fedde alkaloid effective part preparation method, wherein the dicranostigma leptopodum (maxim) fedde alkaloid effective part obtained through chemical steps is a brownish-black powdery solid, and comprises aporphine alkaloid, morphinane alkaloid, protopine alkaloid, protoberberine alkaloid and isoquinoline alkaloid. According to the present invention, with the method, the concentration of the active compound can be effectively improved, the drug taking dose can be lowered, and the pharmacological activity of the dicranostigma leptopodum (maxim) fedde alkaloid can be significantly improved.
Owner:LANZHOU INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Preparation of Saturated Ketone Morphinan Compounds
The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal.
Owner:SPECGX LLC
Alkaloid compound and its preparation method and use
ActiveCN112142667BInhibition releaseGrowth inhibitionOrganic active ingredientsNervous disorderAcyl groupQuinoline
The invention belongs to the technical field of medicine, and relates to alkaloid compounds and their preparation methods and medical applications, in particular to morphinanes and bisbenzylisoquinoline alkaloids and their preparation methods and their preparation for the prevention or treatment of neurodegenerative diseases, Application in antitumor drugs, the structure of the compound is as follows: wherein, R 1 , R 2 is hydroxyl, C1‑C4 acyl; R 3 is C1‑C4 aldehyde group, R 4 , R 9 is C1‑C4 alkoxy, R 5 for hydrogen, R 6 and R 7 form methylenedioxy, R 8 is C1‑C4 alkyl; R 1 'is C1‑C4 alkyl, R 2 ', R 3 ', R 5 ', R 7 'is C1‑C4 alkoxy, R 4 ' is hydrogen, R 6 ' is a C1-C4 aldehyde group.
Owner:SHENYANG PHARMA UNIVERSITY
Processes for the Preparation of Morphinane and Morphinone Compounds
InactiveUS20120046465A1Reduce wasteImprove processing efficiencyOrganic active ingredientsNervous disorderMorphinoneNitrogen
The present application describes processes for the synthesis of morphinane and morphinone compounds, useful as pharmaceutical agents. Also included are novel intermediates useful in the preparation of these compounds. The process comprises quaternization of oripavine to provide a mixture of the R- and S-isomeric (at the nitrogen) quaternary salts. The R-isomer is readily isolated and converted to various N-(R)-morphinane and N-(S)-morphinone compounds. The R-isomer, S-isomer or a mixture of R- and S-isomers may be demethylated and converted to various morphinane and morphinone compounds.
Owner:BROCK UNIVERSITY
Benzomorphan analogs and use thereof
ActiveUS9975854B2Eliminate the effects ofReduce and prevent constipationNervous disorderOrganic chemistryBenzomorphanPharmaceutical medicine
Owner:PURDUE PHARMA LP
Alkaloid compound as well as preparation method and application thereof
ActiveCN112142667AInhibition releaseGrowth inhibitionOrganic active ingredientsNervous disorderAlkaneAcyl group
The invention belongs to the technical field of medicine, and relates to an alkaloid compound and a preparation method and medical application thereof, in particular to morphine alkane and bisbenzyl isoquinoline alkaloids and a preparation method thereof and application of the morphine alkane and bisbenzyl isoquinoline alkaloids in preparation of medicine for preventing or treating neurodegenerative diseases and resisting tumors. The structure of the compounds is shown in the specification, and in the structure formula, R1 and R2 are hydroxyl or C1-C4 acyl, R3 is a C1-C4 aldehyde group, R4 andR9 are C1-C4 alkoxy groups, R5 is hydrogen, R6 and R7 form a methylenedioxy group, R8 is a C1-C4 alkyl group, R1' is a C1-C4 alkyl group, R2', R3', R5' and R7' are C1-C4 alkoxy groups, R4' is hydrogen, and R6' is a C1-C4 aldehyde group.
Owner:SHENYANG PHARMA UNIVERSITY
Processes for preparing morphinans and intermediates thereof
Owner:MALLINCKRODT INC
Opiate intermediates and methods of synthesis
Owner:SPECGX LLC
Therapeutic or prophylactic agent for cachexia
PendingCN114555086AAlleviate concerns about side effectsLess worryOrganic active ingredientsPeptide/protein ingredientsSide effectPharmacometrics
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia, which has few side effects in the treatment of cachexia and exhibits a significant drug effect. The present invention provides a therapeutic or prophylactic agent for cachexia, which is obtained by combining a compound having a morphinane skeleton represented by the following compound or a pharmacologically acceptable acid addition salt thereof with a starvation receptor agonist.
Owner:TORAY IND INC
Benzomorphan analogs and the use thereof
ActiveUS10138207B2Eliminate the effects ofReduce and prevent constipationOrganic active ingredientsNervous disorderBenzomorphanPharmacology
The present invention is directed to Benzomorphan Analog compounds of the Formula I″, Formula IA″, Formula IB″, Formula IC″, or Formula ID″ as shown below; and related Formula I′, Formula IA′, Formula IB′, Formula IC′, or Formula ID′; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R1, R2a, R2b, R3 and R4 are as defined herein.Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
Owner:PURDUE PHARMA LP
Preparation of Hexahydroisoquinolines from Dihydroisoquinolines
ActiveUS20100022776A1Organic chemistryBulk chemical productionSilver tetrafluoroborateBirch reduction
The present invention is directed to processes for the synthesis of morphinans. In particular, a process for the asymmetric reduction of an imine moiety in a 3,4-dihydroisoquinoline to produce a tetrahydroisoquinoline, followed by a Birch reduction to produce a hexahydroisoquinoline. In various embodiments, the 3,4-dihydroisoquinoline contains a phenol moiety protected with a labile protecting group. In other embodiments, the imine reduction reaction mixture contains silver tetrafluoroborate.
Owner:SPECGX LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com